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Purpose: The Convergent procedure is a hybrid, multidisciplinary treatment for symp-
tomatic atrial fibrillation (AF) consisting of minimally invasive surgical epicardial abla-
tion and percutaneous/catheter endocardial ablation. We investigated outcomes following 
introduction of the Convergent procedure at our institution.
Methods: Retrospective study examining single-center outcomes. Demographic, proce-
dural, and post-procedural variables were collected with follow-up data obtained at 3, 6, 
and 12 months.
Results: In all, 36 patients with paroxysmal (11%) or persistent/long-standing persistent 
(89%) AF underwent the Convergent procedure. 36% also underwent concomitant left 
atrial appendage (LAA) exclusion by thoracoscopic placement of an epicardial clip. Mean 
age 60.6 ± 8.0 years with mean arrhythmia burden of 3.9 ± 2.7 years. All patients had failed 
prior attempts at medical management, 81% had failed prior cardioversion, and 17% had 
failed prior catheter ablation. Convergent was performed successfully in all patients with 
no peri-procedural deaths or major complications. At 3 and 12 months, 77.8% and 
77.3% of patients, respectively, were free from symptomatic arrhythmia. 65.8% were off 
anti-arrhythmic medication at 12 months.
Conclusions: The Convergent procedure is safe and has good short- and intermedi-
ate-term clinical success rates. This unique hybrid approach combines strengths of surgi-
cal and catheter ablation and should be part of any comprehensive AF treatment program.
Keywords:  convergent procedure, atrial fibrillation, hybrid ablation, arrhythmia
Introduction
Atrial fibrillation (AF) is a disease that affects more 
than an estimated 3.4–5.9 million people in the United 
States alone.1,2) AF is associated with a negative impact 
on quality of life, is the leading cause of embolic stroke, 
and increases the risk of kidney disease, cardiac valvular 
disease, and heart failure as well as contributes to 
increased healthcare system costs.3–7)
Medical management with an antiarrhythmic and 
anticoagulation regimen has traditionally been first-line 
therapy for patients with AF. This approach, however, 
can be limited by the inherent difficulties and toxicity 
associated with chronic use of these medications. Invasive 
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approaches to treat AF developed starting with the 
first “cut-and-sew” Cox-Maze operation. With advances 
in technology, surgical options developed to include 
numerous minimally invasive approaches for AF abla-
tion. Simultaneously, the development of catheter-based 
endocardial ablation provided a percutaneous option for 
AF treatment. Pulmonary vein isolation (PVI) via radiof-
requency ablation has been the cornerstone of treatment 
for patients with symptomatic, drug refractory AF. PVI 
is the preferred ablation technique for paroxysmal AF, 
with clinical trials demonstrating up to 70% effective-
ness in these patients as compared to 7% success among 
those treated with anti-arrhythmic medical therapy 
alone.8,9) However, the optimal treatment for persistent 
and long-standing persistent AF is less clear. Catheter 
ablation has had limited success in treating these sub-
types of AF with the efficacy of a single catheter ablation 
procedure being reported as low as 20%–30% and with 
multiple procedures increasing the efficacy up to 
50%–60%.9) The reasons for such difficulty in treating 
persistent and long-standing persistent AF are unclear 
but have been postulated to include the presence of 
non-pulmonary vein foci of AF including the posterior 
wall and left atrial appendage (LAA), inherently varying 
electrophysiologic re-entrant circuits, and more advanced 
structural changes including intramyocardial fibrosis 
and anatomic remodeling.
Both catheter and surgical ablation approaches have 
intrinsic limitations. Endocardial catheter ablation, by 
design, is limited in the ability to create linear transmural 
lesions.10–12) Moreover, some aspects of the left atrium, 
including the posterior wall, may be less amenable to 
transmural ablation by catheter approach due to concerns 
about esophageal injury. Surgical ablation techniques, 
on the other hand, lack the ability to define and map the 
electrical properties or the atrial substrate to customize 
the ablation procedure. The Convergent procedure was 
designed to combine the strengths of surgical and cathe-
ter ablation into a single procedure.13–16) This procedure 
is performed in two stages: minimally invasive surgical 
epicardial ablation of the posterior left atrial wall (per-
formed by a cardiac surgeon) followed by endocardial 
ablation (performed by an electrophysiologist) to isolate 
the pulmonary veins and address other portions of the 
left atrium such as the roof line. The hybrid technique 
overcomes the limitations of either the surgical or cathe-
ter approach alone and thereby is thought to improve the 
efficacy in the treatment of refractory or persistent and 
long-standing persistent AF.
We sought to review the outcomes of the first patients 
undergoing the Convergent procedure at our regional 
academic referral center.
Methods
This study is a retrospective analysis of patients that 
underwent the Convergent procedure between February 
2016 and May 2017 at the University of Tennessee Med-
ical Center in Knoxville, Tennessee. These were the first 
patients to undergo the procedure at this institution. The 
IRB of the University of Tennessee Medical Center and 
Graduate School of Medicine approved this study. 
Surgical ablation
The surgical portion of the procedure was performed by 
a single surgeon (LSL). The catheter ablation portion of the 
procedure was performed by three different electrophysiol-
ogists. For the surgical portion, access to the intrapericar-
dial space was achieved via laparoscopic transabdominal 
transdiaphragmatic approach 11 patients, and subxiphoid 
approach in 25 patients. The specific details of the surgical 
technique, including delineation of the location and extent of 
epicardial ablation lesions, have been previously described.16) 
Briefly, general anesthesia is induced via single lumen endo-
tracheal tube (double lumen or bronchial blocker is utilized 
for patients who will undergo concomitant left thoracos-
copy as described below). Once access into the pericardial 
space is obtained, the pericardioscopy SUBTLE cannula 
(AtriCure, Inc., Mason, Ohio, USA) and a 5 mm camera 
scope are inserted. In all patients, sequential epicardial 
superior and inferior ablation lines were performed across 
the posterior left atrium extending from pulmonary vein to 
pulmonary vein using the monopolar Episense device (Atr-
iCure, Inc., Mason, Ohio, USA). Additional ablation lines 
were also placed on the anterior portion of the left inferior 
pulmonary vein and connected to the posterior wall. The 
esophageal temperature was continuously monitored and 
did not increase by more than 1°C from baseline through-
out the surgical portion. In a subset of patients, following 
completion of the epicardial ablation, LAA occlusion was 
performed by placement of an epicardial AtriClip device 
(AtriCure, Inc., Mason, Ohio, USA) via left video-assisted 
thoracoscopic (VATS) approach with real-time transesoph-
ageal echocardiography (TEE) guidance.16)
Endocardial ablation
After the surgical portion of the procedure, the patient 
underwent endocardial ablation. The first four patients 
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had the endocardial portion performed the day after the 
surgical portion, and the remainder of patients had both 
portions completed the same day. This required transpor-
tation of the intubated patient from the operating room to 
the electrophysiology suite. The endocardial catheter 
ablation procedure was a single transeptal technique, and 
CARTO 3D with Pentaray catheter or Lasso catheter was 
used to obtain the atrial and pulmonary vein voltage 
maps (Fig. 1). PVI was accomplished with radiofre-
quency ablation, and any gaps along the posterior wall 
were completed. A roof line and isthmus line were also 
performed. Atrial flutter ablation was performed in some 
patients at the operating physician’s discretion. At the 
end of the procedure, pacing maneuvers were used to 
confirm isolation of all four pulmonary veins as well as 
successful creation of the roof and flutter lines. Direct 
current cardioversion was performed in patients who 
were not in sinus rhythm at the end of the procedure.
Postoperative care
Postoperatively, all patients received a regimen 
consisting of steroids, colchicine, and non-steroidal anti- 
inflammatory medications to combat the expected peri-
carditis. The pericardial and/or pleural drains were 
removed when the output fell below 75 mL for a 24-hour 
period. All preoperative antiarrhythmic medications and 
anticoagulants were resumed prior to discharge.16)
Follow-up
All patients received follow-up at our institution. 
Symptom recurrence was obtained by patient reporting. 
AF recurrence was determined by electronic medical 
record review for documentation of AF on electrocardio-
grams or telemetry strips through emergency department 
visits, outpatient cardiology follow-up visits, or hospital 
admissions. Heart rhythm monitoring was also performed 
on a limited number of subjects by a combination of 
temporary monitoring device (e.g., Holter monitor), 
implantable loop recording device, or permanent existing 
monitoring device. Heart rhythm data were collected 
immediately following the procedure as well as following 
a 90-day post-procedural blanking period. Any episode 
of AF lasting more than 30 seconds after the initial 
90-day blanking period was considered a recurrence. 
Post-procedural outcomes and major complications were 
collected starting immediately following the procedure. 
Statistical analysis
Data were retrospectively collected and entered into 
an electronic database. Statistical analysis was per-
formed with assistance of a statistician. Descriptive and 
frequency statistics were used to answer the research 
questions. Baseline and follow-up values are reported as 
Fig. 1  Representative left atrial voltage map of a patient after the 
epicardial (top) and endocardial (bottom) portions of the 
Convergent procedure. This view is a posterior–anterior 
perspective, with the left and right pulmonary veins being 
on the left and right of the image, respectively. Purple indi-
cates viable electrical signals (and thus sites of AF triggers 
and substrate) and red indicates the absence of electrical 
signals; the goal of ablation is to attain near complete elec-
trical silence (red) of the pulmonary veins and left atrium 
such that AF triggers cannot propagate. The top image 
shows electrical silence of the posterior wall after the epi-
cardial ablation portion of the procedure. This epicardial 
ablation is performed from pulmonary vein to pulmonary 
vein, with the superior extent of ablation determined by the 
location of the pericardial reflection which can vary from 
patient to patient. After completion of the endocardial abla-
tion portion of the procedure (bottom image), there is com-
plete pulmonary vein isolation and electrical silence of the 
left atrium. AF: atrial fibrillation
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mean ± SD for numeric measures and counts and per-
centages for categorical measures. Means and standard 
deviations are reported for continuous variables. Frequency 
and percentage statistics are presented for categorical 
variables. Freedom from recurrence analysis was per-
formed for the total patient population. Analyses were 
conducted using SPSS Version 25 (IBM Corp., Armonk, 
NY, USA).
Table 1 Study patient demographics
Patient characteristic No. of patients % of patients
Sex
 Male 26 72.2%
 Female 10 27.8%
Race
 Caucasian 35 97.2%
 African American  1  2.8%
Hypertension 29 80.6%
Hyperlipidemia 20 55.6%
Coronary artery disease  3  8.3%
Left ventricular hypertrophy 11 30.6%
Obstructive sleep apnea 16 44.4%
Diabetes mellitus 13 36.1%
Left ventricular ejection fraction
 LVEF  50% or greater
 LVEF 31–49%
 LVEF 30% or less
NYHA Class Symptoms
 NYHA Class I
 NYHA Class II
 NYHA Class III
 NYHA Class IV
26
 6
 4
29
 5
 2
 0
72.2%
16.7%
11.1%
80.6%
13.9%
 5.6%
 0.0%
Left atrial size
 Normal (< 4.0 cm)
 Abnormal (> 4.0 cm)
15
21
41.7%
58.3%
Thyroid disorder  4 11.1%
Prior stroke 18 50.0%
Pulmonary hypertension 20 55.6%
COPD  2  5.6%
Tobacco use  4 11.1%
Alcohol use  4 11.1%
Mitral valve disease
 Mitral regurgitation (mild) 25 69.4%
 Mitral regurgitation (moderate)  3  8.3%
 Mitral stenosis (mild)  1  2.8%
Aortic valve disease
 Aortic regurgitation (mild)  6 16.7%
 Aortic stenosis (mild)  1  2.8%
History of atrial flutter
Prior atrial flutter ablation
 8
 7
22.2%
19.4%
Prior atrial fibrillation ablation  6 16.7%
Failed electrical cardioversion 29 80.6%
Failed anti-arrhythmic drugs (AAD)
 Failed 2 AAD
 Failed 3 AAD
 36
 10
 1
100.0%
27.8%
 2.8%
CHADS2Vasc Score
 Score of 2 or less
 Score of 3 or more
16
19
44.4%
52.8%
AAD: anti-arrhythmic drugs; COPD: chronic obstructive pulmonary disease; 
LVEF: left ventricular ejection fraction; NYHA: New York Heart Association
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Results
Baseline patient demographics are listed in Table 1. 
There were a total of 36 patients included in the study. In 
all, 26 (72.2%) patients were men, 35 (97.2%) were Cau-
casian, and the mean age was 61 years. All patients had 
symptomatic AF, with 4 (11.1%) having paroxysmal AF 
and 32 (88.8%) having persistent or long-standing 
persistent AF. All patients had previously failed at least 
one antiarrhythmic medication, 11 (30.5%) had failed at 
least two antiarrhythmic medications, and 29 (80.6%) 
had failed prior electrical cardioversion. Six (16.7%) had 
failed at least one prior catheter ablation and had devel-
oped recurrent AF. The mean BMI was 35.2 kg/m2.
All patients successfully underwent completion of 
both the surgical and catheter ablation portions. In total, 
13 (36.1%) patients underwent concomitant LAA occlu-
sion by epicardial clip placement. At the time of endocar-
dial ablation, 18 (50%) patients underwent right atrial 
flutter line creation, 5 (14%) underwent left atrial flutter 
line creation, and 2 (5%) underwent both right and left 
atrial flutter line creation. All patients were in normal 
sinus rhythm at the time of discharge. Mean follow-up 
was 11.1 + 4.5 months. The 12-month freedom from atrial 
arrhythmia recurrence was 78% (Fig. 2). Of the patients 
who had recurrent AF, 66% occurred in the first 10 patients 
to have the procedure performed, and none of the patients 
with AF recurrence had undergone LAA exclusion.
Arrhythmia recurrence
Eight patients (22%) had recurrent atrial tachyarrhyth-
mia during the 12-month follow-up period, which 
included either recurrent AF, atrial flutter, paroxysmal 
atrial tachycardia, or sinus node dysfunction. Of these 
patients, one underwent repeat endocardial PVI and atrial 
flutter ablation, three underwent cardioversion for atrial 
flutter, two underwent repeat endocardial atrial flutter 
ablation, one underwent atrioventricular (AV) node abla-
tion with permanent pacemaker implantation, and one 
underwent permanent pacemaker implantation. In the 
patients who underwent repeat endocardial voltage map-
ping and ablation, none showed a gap in the posterior left 
atrial wall epicardial ablation site.
When examining the six patients who had previously 
undergone catheter ablation, two had undergone that 
ablation at our institution, and four had undergone 
ablation at an outside facility. We did not have access to 
the outside procedure records, but the records of the 
two patients from our institution did not indicate any 
untoward or particularly abnormal findings that would 
increase the risk of recurrent AF. The EP study at the 
time of the endocardial portion of the Convergent pro-
cedure revealed that four of the six patients had electri-
cal activity in at least one pulmonary vein. The other 
two patients had electrical vein isolation of all four pul-
monary veins but had discernible voltage signals in 
areas of the posterior wall and LAA. At 12-month 
Fig. 2  Procedure success presented as freedom from AF recurrence after the Convergent procedure. The 
three-month blanking period follows current Heart Rhythm Society guidelines for rhythm assessment 
after ablation procedures. AF: atrial fibrillation
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follow-up, three of these six patients remained free 
from arrhythmia recurrence while three had undergone 
repeat EP study and focal catheter ablation for recur-
rent atrial tachyarrhythmia.
Adverse events
Table 2 shows the adverse events and complications 
following the Convergent procedure. There were no 
peri-procedural deaths, need for re-operation, stroke, or 
major complications. No patients required conversion to 
sternotomy or thoracotomy or need for cardiopulmonary 
bypass support. Post-procedure adverse events included 
phrenic nerve palsy (n = 1), severe pericarditis (n = 2) 
requiring extended hospital stay, and significant pericar-
dial effusion requiring pericardiocentesis (n = 3).
Anti-arrhythmic and anticoagulant use
The rates of anti-arrhythmic drug and anticoagulant 
use were decreased following the Convergent procedure 
(Fig. 3). At 12 months after the procedure, there was an 
absolute reduction of 69.4% in patients being treated with 
antiarrhythmic medications and an absolute reduction of 
25% in anticoagulant use.
Discussion
Our initial experience with the Convergent procedure 
demonstrates that this is a safe procedure with good 
short- and intermediate-term outcomes. Our results 
show a 78% freedom from symptomatic AF at one-year 
follow-up, which is similar to Convergent procedure 
success rates reported by others.14–17) Because this patient 
population experiences significant distress and limitations 
due to AF symptoms, we have focused on clinical symp-
tom improvement, rather than purely electrocardiographic 
rhythm recordings, as the primary indicator of procedural 
success. Our findings show that the Convergent procedure 
represents a reasonable therapeutic option to maximize 
likelihood of AF control and symptom relief in the 
difficult-to-treat persistent/long-standing persistent and 
refractory AF patient population.
The major strategic advantage of Convergent over cath-
eter ablation alone is the ability to attain broad area abla-
tion of the entire posterior left atrial wall. PVI alone is 
often insufficient in persistent and long-standing persistent 
AF patients because the arrhythmia triggers and wave-
forms are more likely to be located in non-pulmonary vein 
regions and there may also be associated atrial substrate 
remodeling. Thus, it becomes important to ensure ablation 
of non-pulmonary vein sites such as the posterior left 
atrial wall. Catheter ablation of the posterior wall is lim-
ited in its ability to effect wide area coverage and carries 
the risk of esophageal injury during ablation, which may 
help explain why success rates of catheter ablation for 
these patients are relatively low. One of the most devastat-
ing complications of catheter ablation is atrio-esophageal 
fistula, which can occur since the ablation energy is 
directed from the endocardium outwards away from the 
heart and toward the esophagus. In contrast, with the epi-
cardial ablation during the Convergent procedure the 
posterior wall ablation is performed under direct pericar-
dioscopic vision with the energy source directed from the 
epicardium inwards toward the heart and away from the 
esophagus, thus reducing the risk of esophageal thermal 
injury. Furthermore, with the epicardial ablation catheter, 
there is no return electrode necessary (there is only a 
grounding pad positioned on the lower back) to poten-
tially serve as an inadvertent pathway through the esopha-
gus. The risks of esophageal injury with the surgical part 
of the Convergent procedure stem from collateral damage 
due to elevated tissue temperature adjacent to the catheter 
during ablation line creation. We did not identify any 
esophageal injuries in our series and found excellent 
transmural posterior wall ablation on voltage mapping.
The importance of addressing the LAA in AF patients 
has traditionally revolved around mitigating the risk of 
thromboembolic events originating from within this struc-
ture. More recent studies have implicated the LAA as a 
focus of AF triggers and consequently as a potential inter-
ventional target for rhythm management. Our analysis 
seems to support this view and suggests a likely benefit of 
LAA exclusion in arrhythmia control. We found no AF 
recurrence after the 90-day blanking period in patients 
who had undergone concomitant LAA exclusion. Our 
study was not powered to detect a significant difference 
between patients who did and did not undergo LAA exclu-
sion, but our data trend seems to support the theory that 
Table 2 Adverse events following convergent procedure
Adverse Events
No. of  
patients
% of  
patients
Phrenic nerve palsy 1 2.8
Atrio-esophageal fistula 0 0.0
Cardiac tamponade 1 2.8
Stroke 0 0.0
Death 0 0.0
Pericardial effusion 2 5.6
Pericarditis (severe) 2 5.6
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excluding the LAA augments the success rates of ablation 
alone. The ability to effect electrical silence, and thus 
arrhythmia suppression, is perhaps the key underappreci-
ated benefit of an epicardial LAA clip over percutaneous 
endocardial occlusion devices.18) The molecular or elec-
trophysiologic mechanism by which LAA exclusion 
might contribute to arrhythmia control is unknown. We 
suspect that the LAA is a site of dominant AF triggers in a 
small subset of patients, and that electrical isolation of the 
LAA by epicardial closure may serve as a type of “abla-
tion” of these triggers. Comparison between percutaneous 
endocardial occlusion devices and epicardial exclusion by 
clip placement or complete excision would help better 
elucidate the role of the LAA in AF. LAA exclusion was 
performed in a minority of our patients, but this was due 
primarily to the fact that our group wished to attain famil-
iarity with the new Convergent procedure before includ-
ing the separate LAA exclusion portion. Once we started 
to perform the LAA exclusion, this was completed in all 
patients who could tolerate the single lung ventilation nec-
essary for the thoracoscopic approach.
Our results also demonstrate that the Convergent pro-
cedure can be implemented with good outcomes and an 
excellent safety profile starting with the very first cases in 
an institution. An interesting secondary finding from our 
analysis is that the AF and atrial tachyarrhythmia recur-
rence rate was higher among the earlier patients in the 
series. Our overall atrial tachyarrhythmia recurrence rate 
was approximately 22%, with the majority of these recur-
rences being atrial flutter and occurring in the first 10 
patients of our series. This may suggest that there might 
be a learning curve associated with the procedure, partic-
ularly as it relates to the surgical portion. We suspect this 
learning curve regards the extent of epicardial ablation 
necessary; the extent of ablation should not proceed cau-
dad (or inferior) to the inferior pulmonary veins, since 
ablation of this region (the isthmus) between the inferior 
veins and coronary sinus can increase the risk of perimi-
tral/atypical atrial flutter. An inexperienced surgeon could 
easily inadvertently ablate onto the isthmus due to either 
confusion about anatomic location or lack of understand-
ing of the role the isthmus plays in tachyarrhythmias. 
There are some factors which may confound our conclu-
sion, however. The early patients in our study did not 
have LAA exclusion performed, which, as mentioned 
above, could play a role in AF control. Our study is not 
able to distinguish whether it was operator experience or 
LAA exclusion which led to the different recurrence rates 
in the early versus later patients.
Invasive treatment options such as the Convergent 
procedure are just one component of a multi-faceted 
approach to AF treatment. At our institution, preoperatively, 
we discuss with patients the variables that may contribute 
to ongoing AF including obesity and obstructive sleep 
Fig. 3  Patient prescriptions pre- and post-procedure. Patients were prescribed fewer anti-arrhythmic medications (left) 
and anti-coagulants (right) in the months following the Convergent procedure.
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apnea. All patients are evaluated for these comorbidities 
and referred to appropriate specialists for treatment as part 
of their comprehensive AF treatment paradigm. Our cur-
rent practice is to recommend the Convergent Procedure 
rather than catheter ablation alone for patients with 
symptomatic persistent or long-standing persistent AF 
who have been deemed candidates to pursue ablation 
therapy (i.e., failed medical therapy or cardioversion, 
patient preference for rhythm control, previous catheter 
ablation). We perform concomitant LAA exclusion in 
these patients as long as there are no contraindications 
(i.e., moderate to severe chronic obstructive pulmonary 
disease (COPD), prior left thoracic surgical operations, 
inability to tolerate single lung ventilation).
One challenge in our experience was related to postop-
erative rhythm monitoring. We had considerable difficulty 
in obtaining insurance approval for implantable rhythm 
monitoring devices post-procedure. This limited our abil-
ity to evaluate long periods of rhythm data. A major com-
ponent of our follow-up was patient reporting of symptom 
improvement, since this was the primary concern for all of 
our patients. The majority of patients reported significant 
improvement in quality of life due to reduced AF episode 
symptoms. While we considered AF episodes lasting lon-
ger than 30 seconds to be a recurrence (and procedural fail-
ure) for the purposes of this study, we found that patients 
considered their procedure to be a success if the frequency 
and severity of AF episodes were reduced after the Con-
vergent procedure. This clinical definition may be ultimately 
one of the key benefits of offering a hybrid option such as 
the Convergent procedure since these patients have few 
other successful treatment options. Further studies will 
help to elucidate numerous unanswered questions regarding 
the Convergent procedure including long-term outcomes, 
optimal patient selection, results relative to aggressive and 
newer techniques of catheter ablation, and the role of LAA 
exclusion as part of the overall procedure.
Conclusions
The Convergent procedure is a safe and effective 
treatment option that leverages the strengths of mini-
mally invasive surgery and percutaneous endocardial 
catheter approaches to confer significant symptomatic 
relief from persistent and long-standing persistent AF. 
Such a multidisciplinary, hybrid approach may be the 
key to optimizing outcomes for this difficult patient pop-
ulation and should be considered as part of the armamen-
tarium in a comprehensive AF treatment program.
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